### Edgar Filing: AMARIN CORP PLC\UK - Form 4

AMARIN C	ORP PLC\UK										
Form 4											
December 22											
FORM	FORM 4 UNITED STATES SECUDITIES AND EXCHANCE COMMISSION							т	OMB APPROVAL		
	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549							OMB Number:	3235-0287		
Check this box if no longer subject to Section 16. Form 4 or				GES IN I SECUR		NERSHIP OF	Expires: Estimated a burden hou response	irs per			
Form 5 obligatio may cont <i>See</i> Instru 1(b).	ns Section 17	(a) of the		ility Hold	ing Com	pany	Act of	e Act of 1934, f 1935 or Sectio 40			
(Print or Type I	Responses)										
1. Name and Address of Reporting Person <u>*</u> Abingworth LLP			2. Issuer Name <b>and</b> Ticker or Trading Symbol AMARIN CORP PLC\UK [AMRN]				-	5. Relationship of Reporting Person(s) to Issuer			
(Last)	(First)	(Middle)				. [1 110		(Cheo	ck all applicable	e)	
(Last) (First) (Middle) PRINCE HOUSE, 38 JERMYN STREET			3. Date of Earliest Transaction (Month/Day/Year) 12/20/2011					Director    X10% Owner      Officer (give title    Other (specify below)			
				endment, Date Original onth/Day/Year)				<ul> <li>6. Individual or Joint/Group Filing(Check</li> <li>Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> </ul>			
LONDON,	X0 SW1Y 6DN							Form filed by M Person	More than One Re	eporting	
(City)	(State)	(Zip)	Tabl	e I - Non-D	erivative S	Securit	ties Acc	quired, Disposed o	f, or Beneficial	lly Owned	
1.Title of Security (Instr. 3)	any		emed on Date, if Day/Year)	3.4. Securities AcquiredTransaction(A) or Disposed ofCode(D)(Instr. 8)(Instr. 3, 4 and 5)			Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Ordinary				Code V	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)			
Shares, 50 pence par value per share	12/20/2011			J <u>(1)</u>	11,683 (1)	A	\$ 0 (1)	7,907,509	I (1) (4)	See Notes (1) (4)	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

#### Edgar Filing: AMARIN CORP PLC\UK - Form 4

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactiv Code (Instr. 8)	5. onNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	Number Expiration Date f (Month/Day/Year) Derivative eccurities Acquired A) or Disposed f (D) Instr. 3,		7. Title and of Underlyin Securities (Instr. 3 and	ıg	8. Price Derivat Security (Instr. 5
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to buy)	\$ 1.03					(3)	02/10/2020	Ordinary Shares	7,200	

her

# **Reporting Owners**

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Oth			
Abingworth LLP PRINCE HOUSE, 38 JERMYN STREET LONDON, X0 SW1Y 6DN		Х					
Signatures							
/s/ John Heard, Authorized Signatory	12/22/201	1					
**Signature of Reporting Person	Date						

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Joseph Anderson, a partner of Abingworth LLP (the "Reporting Person"), has been issued, to date, an aggregate of 11,683 ordinary shares, 50 pence par value per share ("Ordinary Shares"), of Amarin Corporation plc (the "Issuer"), in consideration of his services as a director of the Issuer. The Reporting Person is the investment manager to a number of investment funds that include Abingworth Bioventures V L.P. ("ABV V"), Abingworth Bioventures V Co-Invest Growth Equity Fund LP ("AGE") and Abingworth Bioequities

- (1) Master Fund Limited (collectively, the "Abingworth Funds"). Under an agreement entered into between Mr. Anderson and the Reporting Person on December 20, 2011, Mr. Anderson is deemed to hold all of these 11,683 Ordinary Shares (the "Abingworth Shares") on behalf of the Reporting Person for the benefit of the Abingworth Funds (specifically, 5,842 Ordinary Shares are held for the benefit of ABV V and 5,841 Ordinary Shares are held for the benefit of AGE).
- (2) As previously reported, Mr. Anderson was granted an option on February 20, 2010 (the "Grant Date") to purchase 120,000 Ordinary Shares under the Amarin Corporation plc 2002 Stock Option Plan in consideration of his services as a director of the Issuer. Under a prior agreement between Mr. Anderson and the Reporting Person, Mr. Anderson was deemed to hold 103,200 of the 120,000 Ordinary Shares underlying the option for the benefit of ABV V and AGE (51,600 ordinary shares each). Pursuant to an agreement between Mr. Anderson

### Edgar Filing: AMARIN CORP PLC\UK - Form 4

and the Reporting Person entered into on December 20, 2011, Mr. Anderson is now deemed to hold 96,000 of the 120,000 Ordinary Shares underlying the option (the "Abingworth Options") for the benefit of ABV V and AGE (48,000 Ordinary Shares each) and must exercise the Abingworth Options solely upon the direction of the Reporting Person.

The stock option granted to Mr. Anderson initially was scheduled to vest in four equal installments on each anniversary of the Grant Date. However, in light of the Issuer's announcement of favorable data relating to certain of its clinical trials, the Issuer's board of directors

(3) The weeking in fight of the issuer's announcement of ravorable data relating to certain of its eminear thats, the issuer's board of directors approved the acceleration of the vesting schedule relating to certain options (including Mr. Anderson's options) granted by the Issuer, so that all of the vesting dates have been accelerated by a period of six months.

The Reporting Person, on behalf of ABV V or AGE, as applicable, is entitled to direct the disposition of the Abingworth Shares and to receive any proceeds received in connection with the sale or disposition of the Abingworth Shares, and is entitled to the Ordinary Shares issuable upon exercise of the Abingworth Options. The Reporting Person holds the reported securities indirectly through the Abingworth

(4) Funds. The Reporting Person's interest in the securities reported herein is limited to the extent of its pecuniary interest, if any, in the Abingworth Funds. This report shall not be deemed an admission that the Reporting Person, each Abingworth Fund or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.